Rao T S, Kim H S, Lehmann J, Martin L L, Wood P L
CNS Diseases Research, G. D. Searle & Co., c/o Monsanto Co., St. Louis, Mo 63198.
Life Sci. 1989;45(12):1065-72. doi: 10.1016/0024-3205(89)90163-x.
The interactions of phencyclidine (PCP) with the mesocortical dopaminergic system were of interest because of the putative role of this pathway in the etiology of schizophrenia. In the present investigation we examined the effects of PCP, and PCP-receptor agonist, ketamine, on dopamine (DA) release by measuring the levels of 3-methoxytyramine (3-MT), the only DA metabolite which is a reliable indicator of DA release in vivo. PCP increased DA release in the amygdala, pyriform and prefrontal cortices, while ketamine was less potent than PCP in this respect. In contrast to the changes in DA release in the cortical regions, ketamine decreased DA release in striatum, while PCP did not change DA release.
由于中脑皮质多巴胺能系统在精神分裂症病因学中可能发挥的作用，苯环利定（PCP）与该系统的相互作用备受关注。在本研究中，我们通过测量3-甲氧基酪胺（3-MT）的水平来检测PCP及PCP受体激动剂氯胺酮对多巴胺（DA）释放的影响，3-MT是唯一一种在体内可作为DA释放可靠指标的DA代谢产物。PCP增加了杏仁核、梨状皮质和前额叶皮质中的DA释放，而在这方面氯胺酮的作用比PCP弱。与皮质区域DA释放的变化相反，氯胺酮降低了纹状体中的DA释放，而PCP未改变DA释放。
